Objective
"Cancer cost the EU €126 billion in 2009, while in 2010 the US spent a staggering $124.6 billion on treating cancer. This cost is set to rise as the effects of an aging population and increasing life expectancy take their toll. These market drivers will put an intolerable strain on health services across the western world, forcing governments to streamline their health services.
Current cancer treatment is based on the ""average cancer patient"", meaning some cancer patients may not respond to the treatment while others do. Thus it is clearly is a need for solutions that offer precision cancer medicine.
PubGene AS aims to pursue a major market opportunity by developing a complete pipeline for precision cancer medicine (PCMPS), that include the necessary steps from Next Generation Sequencing to clinical treatment support for cancer patients. The biggest beneficiary of PCMPS will be the patient, who will receive a personalized treatment rather than a “hit and miss” approach to therapy. This will improve patient outcomes and ensure patients no longer have to suffer harsh side effects from non-efficacious treatments. The second beneficiaries will be the health providers and payers, as doctors will no longer waste time and money prescribing ineffective treatments. Nevertheless, despite the benefits of personalized cancer medicine, it is crucial to validate and demonstrate the benefits of this type of cancer medicine before large-scale commercialization.
PMCPS is an opportunity for PubGene to expand our suite of applications and enter into complete new market for PubGene - targeting the treatment market. The project will give us a head start in providing tools in the field of personalized cancer medicine, ensuring us strong positions in the future European and worldwide markets. Accomplishment of the project will represent a significant business opportunity with an expected annual turnover of €17 million with a 25-30% annual increase, 3 years after commercialization.
"
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences computer and information sciences data science
- natural sciences computer and information sciences databases
- natural sciences biological sciences genetics mutation
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
0855 OSLO
Norway
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.